PuraPharm Corporation Limited held its Annual General Meeting in Hong Kong on 27 May 2026, where shareholders backed every agenda item with unanimous support.

The poll recorded 300.96 million votes cast for each of the seven resolutions—representing 100% of votes exercised and roughly 56% of the company’s 535.90 million issued shares. No votes were cast against any resolution, and no abstentions or Treasury Shares were recorded.

Key outcomes:

1. Financial Statements Adopted • Shareholders approved the audited consolidated financial statements for the year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board Composition Secured • Eight directors were re-elected, including Executive Directors Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; Non-Executive Director Mr. Dong Zimeng; and Independent Non-Executive Directors Dr. Hung Ting On, John, Dr. Leung Lim Kin, Simon, Mr. Lee Stephen, and Prof. Ng Wang Wai Charles. • The Board was authorised to determine directors’ remuneration.

3. Auditor Re-appointment • BDO Limited was re-appointed as external auditor, with the Board authorised to fix its remuneration.

4. Capital Management Mandates • A share buy-back mandate up to 10% of issued shares and an issuance mandate up to 20% were renewed. • The issuance limit can be extended by the number of shares repurchased under the buy-back mandate.

5. Constitutional Update • A special resolution adopted a second amended and restated memorandum and articles of association, updating the company’s constitutional documents.

Computershare Hong Kong Investor Services Limited acted as scrutineer. No shareholder was required to abstain, and no voting restrictions applied under Hong Kong Listing Rules.

All nine directors, including Chairman and Executive Director Mr. Chan Yu Ling, Abraham, attended the meeting.